戻る Agenda
Proprietary Name Review: International Perspectives from the FDA, Health Canada, and EMA
Session Chair(s)
Lina AlJuburi, PharmD, MSc
Head, Global Regulatory Science and Policy - North America
Sanofi, United States
A trademark that minimizes the risk for medication errors is important to all stakeholders. Learning the role of trademarks and review is critical to the success of the process. An international panel of regulators will discuss the approach they take.
Learning Objective : Discuss trademark development and review processes; Identify the important role of trademarks; Assess take-away points to improve internal company processes.
Speaker(s)
FDA Perspective
Kellie Taylor
FDA, United States
Associate Director, OMEPRM, OSE, CDER, FDA
Health Canada's Revised Guidance For Industry: Review of Brand Names Past, Present, and Future
Cathy A. Parker
Health Canada, Canada
Director General, Biologics & Genetic Therapies Directorate HPFB
EMA Perspective
Isabelle Moulon, MD
European Medicines Agency, Netherlands
Head of Patients and Healthcare Professionals Department